Rapamycin Drug

## What it is Rapamycin (sirolimus) is a macrolide compound originally isolated in 1972 from Streptomyces hygroscopicus, a bacterium found in a soil sample collected on Easter Island (Rapa Nui, hence the name). It was developed by Wyeth (now part of Pfizer) and approved by the FDA in 1999 as Rapamune for the prevention of organ rejection in kidney transplant patients. The compound's mechanism, identified through painstaking work in the 1990s, defined the entire mTOR pathway and earned the targets their name (mTOR stands for 'mechanistic target of rapamycin'). The longevity narrative emerged from a different program. The Interventions Testing Program (ITP), launched by the National Institute on Aging in 2004, screens compounds for lifespan extension in genetically heterogeneous mice across three independent labs. Rapamycin entered the program in 2006 and has consistently extended median and maximum lifespan across multiple cohorts, sexes, and starting ages, including in animals started on rapamycin at 20 months (roughly equivalent to a 60-year-old human). The magnitude is substantial: roughly 9 to 14% in males and 14 to 26% in females depending on dose and starting age. This is the strongest pharmacological lifespan signal in mammals from any compound tested by the program. Use in humans for longevity is entirely off-label. The FDA approved the compound for kidney transplant rejection prevention, certain rare cancers (subependymal giant cell astrocytoma, lymphangioleiomyomatosis), and as a coating on coronary stents. Off-label longevity use is investigational and prescribed by a small number of physicians who have built practices around the protocol; Alan Green and Joan Mannick are among the most public proponents. The PEARL trial (n=114, 5 to 10 mg weekly for 48 weeks, published 2024) is the most relevant human longevity-relevant safety and functional outcome data and reported acceptable safety with some lean-mass and pain-related signals. ## Mechanism of action Rapamycin binds the cytosolic protein FKBP12 with high affinity, and the resulting rapamycin-FKBP12 complex binds and inhibits mTORC1, one of the two main mTOR-containing protein complexes. mTORC1 is a master regulator of cellular nutrient sensing, integrating signals from amino acids, growth factors, cellular energy status, and oxygen availability to control protein synthesis, lipid synthesis, ribosome biogenesis, and autophagy. When mTORC1 is active, it stimulates anabolic processes (translation, growth, proliferation) and suppresses autophagy (the cellular cleanup process by which damaged organelles and protein aggregates are degraded and recycled). mTORC1 inhibition by rapamycin shifts the balance: less anabolism, more autophagy. The leading mechanistic explanation for the longevity effect is that this shift mimics aspects of caloric restriction and improves the cell's ability to maintain proteostasis over time. The second complex, mTORC2, is less directly inhibited by acute rapamycin exposure but is suppressed by chronic continuous dosing. Chronic mTORC2 inhibition appears to drive several of the metabolic side effects observed in transplant patients on daily dosing (insulin resistance, hyperlipidemia). The longevity protocol's reliance on weekly rather than daily dosing is the explicit attempt to keep mTORC1 suppressed during the dosing window while allowing mTORC2 to recover between doses. Pharmacokinetics support weekly dosing. Oral rapamycin reaches peak plasma concentrations roughly 1 to 2 hours after dosing. The terminal half-life is around 62 hours in healthy adults, with substantial individual variation. Steady state on weekly dosing is reached in roughly 2 to 4 weeks. Bioavailability varies enormously by formulation and food state; the standard recommendation is to take it consistently with or without a high-fat meal because food substantially raises absorption. ## Evidence base by outcome ### Lifespan extension in mice The ITP results are the most replicable single finding in geroscience. Multiple cohorts, multiple sexes, multiple labs, multiple starting ages, all positive. The 2009 Harrison paper in Nature was the first major report; subsequent ITP cohorts have replicated and extended the effect. Magnitude is dose-dependent: 14 ppm in food (roughly 2.2 mg/kg/day equivalent in a mouse) produces larger effects than 4 ppm. Late-life initiation (20 months) still produces meaningful lifespan extension, distinguishing rapamycin from interventions that require lifelong administration. ### Healthspan and immune function in elderly humans The Mannick trials (2014, 2018, 2021) tested the rapamycin analog everolimus and the related compound RTB101 in older adults and reported improved influenza vaccine antibody response, fewer respiratory tract infections, and better immune function biomarkers. The trials enrolled around 200 to 650 adults each at low intermittent doses. The signal is consistent with the immune-rejuvenation hypothesis but the agents tested were not rapamycin itself. ### PEARL trial The PEARL trial (Kaeberlein and colleagues) randomized 114 healthy adults aged 50 to 85 to placebo, 5 mg weekly, or 10 mg weekly for 48 weeks. Primary outcome was a composite of body composition, blood biomarkers, and pain. The headline result was that rapamycin was acceptably safe at these doses, with a modest signal for improved lean mass and reduced pain in women on 10 mg weekly. The trial was not powered for hard endpoints. It is the best-designed human longevity-relevant trial of rapamycin to date and remains far short of the evidence base required for a conventional clinical recommendation. ### Established clinical indications In renal transplantation, rapamycin is a well-established immunosuppressant with substantial outcome data across thousands of patients. It is associated with lower rates of de novo solid tumors and skin cancers compared to calcineurin-inhibitor-based regimens, which is part of the mechanistic case for its longevity effects. The transplant evidence base also defines the side-effect profile that longevity users are trying to avoid. ### Cellular senescence and SASP Multiple preclinical studies report that rapamycin reduces the secretion of inflammatory cytokines from senescent cells (the senescence-associated secretory phenotype, or SASP). This is mechanistically aligned with the longevity hypothesis. Translation to humans is inferential rather than directly demonstrated. ## Dosage and administration The canonical longevity protocol is 5 to 10 mg taken orally once weekly with food. Some protocols start at 2 to 5 mg weekly and titrate up based on tolerability and trough levels. Trough sirolimus levels in the longevity protocol are typically aimed at the low end of the therapeutic transplant range or below, since the goal is intermittent mTORC1 inhibition rather than continuous immunosuppression. Food timing matters. A high-fat meal raises sirolimus AUC by roughly 35% and Cmax by roughly 65% versus the fasted state. Consistency is more important than fasted-versus-fed; pick one and stick with it for predictable exposure. Weekly cycling is the practical heart of the protocol. The rationale is that mTORC1 stays suppressed during the high-exposure window after dosing, but the long inter-dose interval allows mTORC2 to recover and avoids the chronic metabolic side effects observed in daily-dosed transplant patients. The 6 to 7 day interval roughly matches one half-life-decay cycle and is empirical rather than precisely optimized. No consensus exists on duration. Some longevity protocols include planned washouts (1 month off every 6 months) on theoretical grounds; others run continuous weekly dosing indefinitely. The empirical case for either is thin. ## Side effects and safety Mouth ulcers (stomatitis) are the most common and most dose-limiting side effect, affecting roughly 20 to 40% of users at 8 to 10 mg weekly. They typically appear within 2 to 4 weeks of starting, manifest as small painful aphthous-style ulcers, and resolve within 1 to 2 weeks of dose reduction. Acne-like rash and mild GI upset follow. Hyperlipidemia (raised LDL and triglycerides) is dose-dependent and observed in transplant patients at daily dosing. Weekly dosing produces smaller lipid changes but they are detectable in some longevity users. Glucose intolerance and insulin resistance are similarly dose-dependent and are part of the rationale for weekly rather than daily dosing. Delayed wound healing is a documented effect that matters operationally. Surgery (including dental procedures) typically calls for stopping rapamycin 2 to 4 weeks before and resuming after wound closure. Live vaccines should be timed away from the dosing window because of the immunosuppressive effect; inactivated vaccines are fine. Contraindications include active infection, severe hepatic impairment, planned surgery, pregnancy, and unmonitored use without baseline labs. The 'longevity protocol' framing should not obscure the fact that this is an immunosuppressant; users with chronic infections or compromised immune systems carry meaningfully higher risk than the trial populations. Drug interactions through CYP3A4 are major. Strong CYP3A4 inhibitors (ketoconazole, clarithromycin, grapefruit juice) substantially raise rapamycin exposure and can produce toxic levels even at low oral doses. Strong CYP3A4 inducers (rifampin, St John's wort) reduce levels and effectiveness. ACE inhibitors raise angioedema risk modestly. The grapefruit interaction is the one most likely to surprise users who are not used to managing CYP3A4 substrates. ## Stack interactions and timing Rapamycin pairs in some longevity protocols with metformin, an SGLT2 inhibitor, or other geroprotectors. The combinatorial evidence is essentially absent in humans. The most defensible stacking is with whatever is independently indicated for cardiovascular risk and metabolic health, since rapamycin's own effects on lipids and glucose make those domains worth monitoring more closely. Timing within the week is flexible. Most users dose on a fixed weekly day to make adherence trivial. Some protocols suggest dosing 24 hours after a heavy resistance training session to avoid blunting muscle protein synthesis acutely, but this is mechanistic speculation rather than evidence-based optimization. Protein intake during the high-exposure window is sometimes restricted on the rationale that mTORC1 inhibition during high amino acid intake is wasteful. The trial evidence does not support this nuance. ## Practical notes The compound is prescription-only and is generally accessed through telehealth services that have built practices around the longevity indication, or through compounding pharmacies, or through international generic sources (sirolimus is off-patent and widely available globally as a generic). Quality and trough-level confirmation become critical when moving away from the standard supply chain. Trough sirolimus levels are inexpensive to measure and worth doing periodically to confirm exposure is in the intended range. Baseline labs before starting include lipid panel, fasting glucose and HbA1c, comprehensive metabolic panel, and CBC. Repeat at 3 and 6 months and annually thereafter. Trough sirolimus level after 4 weeks of weekly dosing confirms exposure. Expect side-effect issues in the first 4 to 8 weeks of dose escalation. Stomatitis is the most common reason for dose reduction and is typically managed by dropping from 10 mg to 5 to 7 mg weekly. The honest framing for the longevity use case: this is investigational, the evidence base is heavy in mice and thin in humans, and the side-effect profile is real. Anyone using rapamycin off-label for longevity is making an informed bet on incomplete data, not following a settled clinical recommendation.